Table 5.
The results of the studies on efficacy of the use of convalescent plasma for COVID-19 treatment.
| № | Authors, Year | The Type of Research | Treatment Patients Characteristic, n |
Conclusions | |
|---|---|---|---|---|---|
| Studied Group | Comparison Group | ||||
| 1 | Simonovich VA et al. [68] | Double-blind, placebo-controlled, multicenter tria | Severe COVID-19 n = 228 Early administration of convalescent plasma (median titer of 1:3200 of total SARS-CoV-2 antibodies) |
Severe COVID-19 n = 105 placebo |
No difference |
| 2 | Libster R et al. [69] | A randomized, double-blind, placebo-controlled trial | Mildly ill infected older adults n = 80 Early administration of high-titer convalescent plasma 250 mL (IgG titer greater than 1:1000 against SARS-CoV-2 spike) |
Mildly ill infected older adults n = 80 placebo |
No statistical difference reduced the progression of COVID-19 |
| 3 | Salazar E et al. [70] | Prospective, ongoing study | Severe and/or life-threatening COVID-19 n = 136 600 mL plasma was collected from each donor 7 and 14 days |
Severe and/or life-threatening COVID-19 n = 251 |
Decreaesd mortality |
| 4 | Khamis F et al. [71] | Single-center, case series study |
n = 11 Early therapeutic plasma exchange (TPE), 14, 28 days |
Critical COVID-19 n = 20 |
Decreased mortality |
| 5 | Li L et al. [72] | Open-label, multicenter, randomized clinical trial | Severe or life-threatening COVID-19 n = 52 specific IgG titer ≥ 1:640; 200 mL of plasma 28 days |
Severe or life-threatening COVID-19 n = 51 |
No difference |
| 6 | Gharbharan A et al. [73] | A randomized trial |
n = 43 ≥1:80; 300 mL 15 days |
n = 43 | No statistical difference Mortality 14.0 vs. 26.0 |
| 7 | Agarwal A at al [74] | Open label, parallel arm, phase II, multicentre, randomised controlled trial. | Moderate COIVD-19 n = 235 2 doses of 200 mL CP |
n = 229 | No statistical difference Mortality: 14.5 vs. 13.5 |
| 8 | Joyner MJ et al. [75] | Open-label, Expanded Access Program (EAP) for the treatment of COVID-19 patients with human convalescent plasma. | Severe critical COVID-19 n = 35 150–200 mL 30 days |
n = 322 | Decreased mortality |
| 9 | Liu STH et al. [76] | Retrospective, propensity score-matched case-control study | Severe or life-threatening COVID-19 2 units of CP; 1:320 14 days n = 39 |
Severe or life-threatening COVID-19 n = 156 |
No diference |